Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Carcinoma, Basal Cell 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 259Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45cemiplimab 42Specimen Handling 42CTLA-4 Antigen 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × remetinostat × Dermatologic × Clear all
NCT03180528 2021-06-08

Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

Stanford University

Phase 2 Completed
30 enrolled 10 charts
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡